A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors

Exclusion Criteria

• •1. History of ≥2 primary malignancies within 5 years prior to informed consent.
• •2. Received chemotherapy within 3 weeks, radiotherapy within 4 weeks, or biologic, endocrine, or immunotherapy within 4 weeks before dosing.
• •3. Medication of other unmarketed investigational drugs or therapies within 4 weeks before dosing.
• •4. Brain metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression.
• •5. Underwent major organ surgery (excluding biopsy) or significant trauma within 4 weeks before the first dose of investigational drug or requiring elective surgery during the study.
• •6. Previous or concurrent gastrointestinal perforation, surgical procedures and wound healing complications, as well as bleeding events.
• •7. Received intravenous thrombolysis treatment within 2 weeks, except for preventive anticoagulation and antiplatelet therapy.
• •8. Vaccinated within 4 weeks before dosing.
• •9. Treated with systemic corticosteroids within 14 days before dosing.
• •10. Severe lung disease affecting pulmonary function.
• •11. Active systemic infection requiring treatment within 7 days before dosing.
• •12. Uncontrolled third-space effusion.
• •13. Serious cardiovascular or cerebrovascular diseases.
• •14. Known hypersensitivity or delayed allergic reaction to the investigational product or its components.
• •15. Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.
• •16. Known alcohol or drug dependence.
• •17. Pregnant or breastfeeding women, or individuals planning to conceive.